Blueprint Medicines to Present at Upcoming Investor Conferences
Blueprint Medicines Corporation (Nasdaq: BPMC) announced its participation in two upcoming investor conferences. The first is the 22nd Annual Needham Healthcare Conference, taking place virtually on April 18, 2023, at 2:15 p.m. ET. The second is the Stifel 2023 Targeted Oncology Days, scheduled for April 25, 2023, at 11:30 a.m. ET. Webcasts of each presentation will be accessible on the company's website, with replays archived for 30 days post-event.
Blueprint Medicines focuses on inventing precision therapies for cancer and blood disorders, utilizing advanced molecular targeting and drug design since 2011. The company aims to deliver therapies that target genetic drivers in various types of cancer, including systemic mastocytosis and lung cancer, in the U.S. and Europe.
- None.
- None.
CAMBRIDGE, Mass., April 11, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced its participation in the following upcoming investor conferences:
- 22nd Annual Needham Healthcare Conference, held virtually, on Tuesday, April 18, 2023 at 2:15 p.m. ET.
- Stifel 2023 Targeted Oncology Days, held virtually, on Tuesday, April 25, 2023 at 11:30 a.m. ET.
A live webcast of each presentation will be available by visiting the "Events and Presentations" section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcasts will be archived on Blueprint Medicines' website for 30 days following each presentation.
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering our approved medicines to patients in the United States and Europe, and we are globally advancing multiple programs for systemic mastocytosis, lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-upcoming-investor-conferences-301793758.html
SOURCE Blueprint Medicines Corporation
FAQ
When will Blueprint Medicines present at the Needham Healthcare Conference?
What is the date of the Stifel 2023 Targeted Oncology Days?
How can I access the live webcasts for Blueprint Medicines' presentations?
What type of therapies does Blueprint Medicines develop?
Where can I find more information about Blueprint Medicines?
